Abstract
In 2022, the post-pandemic period, the health sector stocks had a big difference in price performance between different stocks. Some stocks rose significantly because of the vaccines and specific drugs for covid-19, while others' growth slowed down or even had negative profit margins because people were afraid to go to the hospital which cause a reduction of other drugs' sales volume. In the health sectors, there're companies that research and development of drugs, distribute drugs, make medical apparatus and instruments, and even have some "grocery stores" like CVS. It might be difficult to find which stocks are worth the cost of implementation in the post-pandemic period and the special increase because Covid-19 has ended. This paper will analyze 3 stocks as an example to show the investment decisions between different investors. By using risk analysis, profit analysis, and market analysis, this paper will show the investment value of 3 stocks: CVS, MCK, and WBA. These analyses are based on PE, PB, ROA, ROE, profit margin, and many other ratios in 2022. This article will help people choose the health sector stocks. In the conclusion, MCK has the most investment value in 2023 and MCK has a stable income with low risk. WBA may be a bad choice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
